Basal Cell Carcinoma Clinical Trial
Official title:
Melanocyte Features and Its Influence in Pigmentation in Basal Cell Carcinoma in the Mexican Population
Basal cell carcinoma (BCC) is the most frequent neoplasia worldwide. There are more than 30 histopathologic subtypes, however the nodular subtype is the most common. Pigmented varieties are common in darker skin types, therefore in our country. Previous studies have shown an increase number and size of melanocytes. Melanogenesis were increased at the expense of hyperfunctioning melanocytes as well. The aim of the study was to describe the characteristics of melanocytes in pigmented and non-pigmented variants of basal cell carcinoma.
Melanocytes are highly specialized dendritic cells that performs multiple functions through
autocrine, paracrine and endocrine mechanisms. These cells are part of a complex system of
intercellular communication along with keratinocytes, Langerhans cells and fibroblasts. This
intricate network of cellular communication is possible thanks to interaction with
cytokines, growth factors and neurotransmitters. Although melanocytes perform brilliantly
immunoregulatory and neuroendocrine functions, their fundamental role is to offer protection
against the harmful effects of UV radiation through production and transference of melanin
to keratinocytes, a process better known as melanogenesis. The latter requires 3 basic
proteins to ensure photoprotection: MC1R (activation), MITF (traduction) and TYR (melanin
synthesis).
If one of the main features of melanocytes is to avoid UV radiation injurious effect, thus
it raises many questions regarding the possible relation between these cells and skin
cancer. Currently a great number of melanocytic alterations have been described in melanoma;
however in non-melanoma skin cancer the role of melanocytes is less clear. Basal cell
carcinoma (BCC) is the most frequent neoplasia worldwide. There are more than 30
histopathologic subtypes, however the nodular subtype is the most common. Pigmented
varieties are common in darker skin types, therefore in our country. Previous studies have
shown an increase number and size of melanocytes. Melanogenesis were increased at the
expense of hyperfunctioning melanocytes as well. In our experience we have noticed the
clinical course regarding pigmented nodular basal cell carcinoma is more benign when
compared to those without pigment. Most studies regarding the role of melanocytes and
pigmentation in basal cell carcinoma have been conducted in caucasian populations, and
therefore not representative of what may occur in mestizo population. The aim of the study
was to describe the characteristics of melanocytes in pigmented and non-pigmented variants
of basal cell carcinoma. Quantify the expression of melanocytic maturation: transcription
factors (SOX9 and SOX10), focal adhesion kinase (FAK125) and receptor tyrosine kinase
(c-KIT) and melanogenesis such as melanocortin 1 receptor (MC1R), microphthalmia-associated
transcription factor (MITF) and tyrosinase (TYR) markers. Investigate the tumoral
microenvironment through the quantification of melanin, mast cells, angiogenesis and solar
elastosis.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT05608902 -
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
|
||
Completed |
NCT05077033 -
Intratumoral phIL12 GET
|
Phase 1 | |
Active, not recruiting |
NCT04928222 -
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04929535 -
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
|
Phase 2 | |
Completed |
NCT02662244 -
Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
|
N/A | |
Completed |
NCT00959647 -
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
|
Phase 2 | |
Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
Completed |
NCT00473343 -
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT06024629 -
cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
|
||
Not yet recruiting |
NCT05324202 -
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
|
N/A | |
Withdrawn |
NCT04099446 -
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
|
||
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT01260987 -
Fractional CO2 Laser Assisted Photodynamic Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT01201915 -
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01208831 -
An East Asian Study of LDE225
|
Phase 1 | |
Completed |
NCT01014819 -
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
|
N/A | |
Completed |
NCT00472043 -
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma
|
Phase 3 |